Aspirin for Preeclampsia and Pregnancy Loss Prevention
Early Double Low-Dose Aspirin to Reduce Preeclampsia and Miscarriage: a Global Approach RCT
This project explores if taking a slightly higher dose of aspirin very early in pregnancy can help prevent both preeclampsia and pregnancy loss.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11158899 on NIH RePORTER |
What this research studies
We are looking into whether taking 162 mg of aspirin daily, starting as soon as you know you are pregnant (up to 6 weeks' gestation), can offer better protection. Current guidelines suggest a lower dose of aspirin starting later in pregnancy to prevent preeclampsia, but we believe an earlier start with a slightly higher dose might also help prevent pregnancy loss. This work involves a randomized comparison to see if this new approach is more effective. Participants will be recruited through the Penn Medicine system to ensure early detection of pregnancy and timely start of the study intervention.
Who could benefit from this research
Good fit: Ideal candidates are pregnant individuals who receive a positive pregnancy test early in their pregnancy, up to 6 weeks' gestation.
Not a fit: Patients who are already past 6 weeks' gestation or who have contraindications to aspirin may not be suitable for this specific approach.
Why it matters
Potential benefit: If successful, this approach could offer a simple and effective way to reduce the risks of preeclampsia and pregnancy loss for many pregnant individuals.
How similar studies have performed: Aspirin is already recommended for preeclampsia prevention, and this work builds on existing data suggesting that earlier and higher doses might offer greater protection, making this a novel extension of a known therapy.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Schisterman, Enrique F. — University of Pennsylvania
- Study coordinator: Schisterman, Enrique F.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.